Keyphrases
Pediatric
100%
Complete Response
100%
Wilms Tumor
100%
MEK Inhibitor (MEKi)
100%
BRAF V600E
100%
BRAF V600E mutation
60%
Overall Survival
40%
Melanoma
20%
Dabrafenib
20%
Trametinib
20%
Therapeutic Potential
20%
Effective Treatment
20%
Epithelial Phenotype
20%
Clinical Course
20%
Combination Treatment
20%
Conventional Chemotherapy
20%
Combination Therapy
20%
Current Therapies
20%
Treatment Side Effects
20%
Radiological Response
20%
Tumor Patients
20%
Next-generation Sequencing
20%
BRAF Inhibitor (BRAFi)
20%
Pulmonary Nodule
20%
Salvage Chemotherapy
20%
Molecular Targeted Therapy
20%
Childhood Malignancy
20%
Renal Malignancy
20%
Minimal Treatment
20%
Inhibitor Combination
20%
Favorable Histology
20%
Salvage Radiation
20%
Medicine and Dentistry
Pediatrics
100%
Wilms' Tumor
100%
Overall Survival
40%
Disease
20%
Recurrent Disease
20%
Nodular Melanoma
20%
Malignant Neoplasm
20%
Cancer
20%
Side Effect
20%
Dabrafenib
20%
Trametinib
20%
Combination Therapy
20%
Disease Course
20%
Lung Nodule
20%
Childhood Cancer
20%
MEK Inhibitor
20%
Next Generation Sequencing
20%
Molecularly Targeted Therapy
20%